Asco: Follow Up Of Lifileucel Treatment
Abstract No : 10006
Indication : Melanoma
Intervention : lifileucel (LN-144)
Company : Iovance Biotherapeutics, Inc.
Technology : TIL
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant.
View More: https://www.delveinsight.com/asco-conference/article/lifileucel-LN-144
ASCO: Pegilodecakin
Abstract No : 9563
Abstract Type : Poster Session
Indication : PD-L1 selected NSCLC
Intervention : Pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P
Company : Eli Lilly and Company
Technology : Monoclonal antibody
Adding PEG to P did not lead to improvement in ORR, PFS, or OS, in 1L advanced NSCLC with high PD-L1 expression. PEG+P arm demonstrated expected safety profile but overall higher toxicity compared to pembrolizumab alone.
View More: https://www.delveinsight.com/asco-conference/article/NCT03382899
ASCO: Results from DREAMM-2 study
Abstract No : 8536
Abstract Type : Poster Discussion Session
Indication : Multiple Myeloma
Intervention : Belantamab mafodotin
Company : GlaxoSmithKline
Technology : BCMA Inhibitor
Belantamab mafodotin (GSK2857916) sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated RRMM. Being the first in class BCMA targeting ADC gives it a significant advantage over its competitors
View More: https://www.delveinsight.com/asco-conference/article/NCT03525678
ESMO Abstracts:
CheckMate 238 Results at ESMO 2020
Abstract No : Abstract: #1076O
Indication : Melanoma
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
NIVO continued to demonstrate improved RFS and DMFS vs IPI at 48 mo in pts with stage III/IV melanoma at high risk of recurrence. OS events (n = 211) were lower than anticipated (n = 302). OS rates were similar to NIVO and IPI, although use of subsequent IO therapy was higher in the IPI arm. Late-emergent TRAEs were consistent with the established safety profile of NIVO and IPI, with more events reported with IPI.
View More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-238-NCT02388906-esmo-2020
CHRYSALIS study results at ESMO 2020
Abstract No : Abstract 1258O
Indication : Non-small cell lung cancer
Intervention : Amivantamab + lazertinib
Company : CHRYSALIS study
Technology : EGFR-MET bispecific antibody + TKI
Amivantamab (JNJ-61186372) can be combined safely with lazertinib at their respective full monotherapy doses. Encouraging preliminary activity was observed in osimertinib-relapsed disease
View More: https://www.delveinsight.com/esmo-conference-2020/article/chrysalis-study-NCT02609776-esmo-2020
PALLAS Trial: adjuvant palbociclib with endocrine therapy vs. endocrine therapy alone for HR+/HER2- early breast cancer
Abstract No : Presentation LBA12
Indication : Breast cancer
Intervention : Palbociclib
Company : Pfizer
Technology : CDK4/6 Inhibitor
Within the PALLAS trial, at IA2, two years of adjuvant palbociclib with ET did not improve iDFS compared to ET alone. Ongoing long-term follow-up and additional clinical and translational analyses will explore the effect of P in this patient population.
View More: https://www.delveinsight.com/esmo-conference-2020/article/PALLAS-pfizer-esmo-2020
About Delveinsight
DelveInsight is a leading Business Consultant, and Pharmaceutical Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
